PBE vs. XBI
Compare and contrast key facts about Invesco Dynamic Biotechnology & Genome ETF (PBE) and SPDR S&P Biotech ETF (XBI).
PBE and XBI are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. PBE is a passively managed fund by Invesco that tracks the performance of the Dynamic Biotech & Genome Intellidex Index (AMEX). It was launched on Jun 23, 2005. XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006. Both PBE and XBI are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: PBE or XBI.
Correlation
The correlation between PBE and XBI is 0.90, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Performance
PBE vs. XBI - Performance Comparison
Key characteristics
PBE:
0.31
XBI:
0.41
PBE:
0.56
XBI:
0.74
PBE:
1.07
XBI:
1.09
PBE:
0.20
XBI:
0.20
PBE:
1.34
XBI:
1.29
PBE:
4.37%
XBI:
8.18%
PBE:
18.58%
XBI:
25.90%
PBE:
-45.69%
XBI:
-63.89%
PBE:
-19.74%
XBI:
-47.44%
Returns By Period
In the year-to-date period, PBE achieves a 2.15% return, which is significantly lower than XBI's 2.37% return. Over the past 10 years, PBE has underperformed XBI with an annualized return of 3.42%, while XBI has yielded a comparatively higher 4.32% annualized return.
PBE
2.15%
-0.62%
3.23%
3.91%
3.57%
3.42%
XBI
2.37%
-3.20%
-1.05%
4.32%
-1.28%
4.32%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
PBE vs. XBI - Expense Ratio Comparison
PBE has a 0.59% expense ratio, which is higher than XBI's 0.35% expense ratio.
Risk-Adjusted Performance
PBE vs. XBI - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Invesco Dynamic Biotechnology & Genome ETF (PBE) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
PBE vs. XBI - Dividend Comparison
PBE's dividend yield for the trailing twelve months is around 0.05%, less than XBI's 0.14% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
PBE Invesco Dynamic Biotechnology & Genome ETF | 0.05% | 0.02% | 0.00% | 0.00% | 0.04% | 0.00% | 0.00% | 0.57% | 0.38% | 1.12% | 0.55% | 0.00% |
XBI SPDR S&P Biotech ETF | 0.14% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% | 1.07% | 0.17% |
Drawdowns
PBE vs. XBI - Drawdown Comparison
The maximum PBE drawdown since its inception was -45.69%, smaller than the maximum XBI drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for PBE and XBI. For additional features, visit the drawdowns tool.
Volatility
PBE vs. XBI - Volatility Comparison
The current volatility for Invesco Dynamic Biotechnology & Genome ETF (PBE) is 5.85%, while SPDR S&P Biotech ETF (XBI) has a volatility of 7.92%. This indicates that PBE experiences smaller price fluctuations and is considered to be less risky than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.